UK 04:57 Sunday, 27 September 2026
Breaking news and expert analysis on fast-moving AIM and LSE listed shares
Four Premaitha (NIPT) bods presented and faced the music at the UK Investor City forum last week. I was hard on them with my questions as were other members of the audience. But I think they coped well and the shares are most certainly a BUY. Enjoy the video and remember that the next forum (featuring Sosandar) is on 3 December. We will start taking bookings next week.
Tom Winnifrith writes: For the second time Premaitha (NIPT) has served up a trading update for the six months to 30 September and thus having heard the news before it is hardly shocking. FFS do its PR folks think we are stupid or what? Answering my own question, the self important, over-paid, halfwitted knobheads probably do.
There are now just the last 5 ( of 120) places left for the next Wray family organised UK Investor evening seminar in central London. So if you want to book a slot do so now HERE. The event kicks off with drinks and canapes from 5.30 with the first talk just after six. It will be a packed evening.
I am looking forward to grilling Premaitha (NIPT) at the Nigel Wray London seminar on 16 October. There are still a few places going and its free – details HERE. Meanwhile we have three pieces of news this week following that rather disappointing placing at 10p two Friday's ago caused by the a’hole behaviour of the toads at FinnCap. Yes this is Tom Winnifrith writing…
Under promise and over deliver is what PR poltroons tell their AIM clients. So you say you are looking to raise x but know you will raise x and a bit and then call it a massive success even if the placing is only at 66% of the share price a week or so earlier.
Tom Winnifrith writes and has also discussed this in bearcast HERE: We ordinary shareholders in Premaitha (NIPT) have suffered for many years and shown enormous loyalty. News released well after the market close of a £2.5 million placing at 10p might thus seem like a kick in the teeth by a management treating us with contempt. I am afraid the story is far worse.
We have only been waiting three years for this and in the end it came as a complete surprise but a very pleasant one at that. At last Premaitha (NIPT) has settled its patent dispute with American bully boy giants Illumina. This bolt from the blue is great news and now means that a rapidly growing and profitable business will be, at last, valued on fundamentals and that will drive a re-rate which appears to be underway already.
We are getting increasingly used to Premaitha (NIPT) announcing more and more large non-UK distribution agreements. And fear not there will be much more on that front in the weeks and months that lie ahead. It will be a hot summer for Premaitha and for we loyal shareholders. But, for now, there is something a bit different.
The rehabilitation of Premaitha Health (NIPT) continues. The latest news is from India where there is not even a whiff of a patent challenge from Illumina and where our boys have signed a 3-year agreement with one of the most advanced clinical laboratory groups in the country to provide a bespoke, high quality and scaleable NIPT solution.
Let's declare an interest first. FIML, a company owned via a Trust by dependents of Tom Winnifrith, took part in the placing at 4.5p but was scaled back so topped up with market purchases at 6.9p.
It is the house broker so not impartial. I think the target for Premaitha (NIPT) is too low and bought more shares this morning in the secondary market. But here is the Finncap take in a 20 page note:
